New JN.1 Covid variant cases surge in Singapore, Hong Kong, Thailand: Should India be worried?
Live Events
Neighbours see significant increases
New variants driving spread
Immunity is waning, say officials
India remains cautious, not complacent
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
As several Asian countries witness a sharp uptick in Covid-19 cases, Indian health authorities have said the situation at home remains 'under control', with only a slight rise in some states.According to officials quoted by PTI, India reported 257 active cases as of 19 May 2025. 'As per the preliminary information available, the cases are mostly mild, not associated with unusual severity or mortality,' an official said. The central government is closely monitoring the developments and has increased health surveillance nationwide.A review meeting was held in New Delhi on Monday. It was chaired by the Director General of Health Services and included senior experts from the National Centre for Disease Control (NCDC), Emergency Medical Relief (EMR) division, Disaster Management Cell, Indian Council of Medical Research (ICMR), and major central government hospitals.Officials concluded that while the region is seeing a surge, 'the number of cases seen until Monday was very low considering the large population of the country.' They also confirmed that almost all cases in India have been mild and did not require hospitalisation.'A robust system for surveillance of respiratory viral illnesses, including Covid-19, also exists in the country through the Integrated Disease Surveillance Programme (IDSP) and ICMR,' an official noted.The latest Covid-19 wave sweeping across Southeast Asia has led to alarming case numbers. In Singapore, the Ministry of Health reported 14,200 cases in the week of 27 April to 3 May 2025, up from 11,100 the previous week. Hospitalisations rose too, from 102 to 133 per day. However, the number of intensive care patients dropped from three to two daily.'The hospitals are currently able to manage the increase in cases,' the Singapore Health Ministry stated in its report.Thailand has seen a bigger jump. Between 11 and 17 May, the country reported 33,030 new infections, with over 6,000 of them in Bangkok alone. According to the Department of Disease Control, this surge was likely fuelled by holiday travel during Songkran, the Thai New Year, held from 13 to 15 April.In Hong Kong, test positivity rates more than doubled in four weeks — from 6.21% to 13.66% between early and mid-April. 'After the resumption of normalcy, Hong Kong experienced cycles of active periods of Covid-19 in every six to nine months,' said Dr Edwin Tsui, Controller of the Centre for Health Protection.Even mainland China reported an increase between 31 March and 4 May. The Chinese CDC noted a jump in Covid positivity among patients with flu-like symptoms, rising from 7.5% to 16.2%. Among hospitalised patients, the rate nearly doubled — from 3.3% to 6.3%.Health experts point to the spread of new Omicron-related variants as a major factor behind the resurgence. Singapore has confirmed that LF.7 and NB.1.8 — both sub-lineages of the JN.1 variant — now account for more than two-thirds of all sequenced Covid cases there.'At present, LF.7 and NB.1.8 (both descendants of the JN.1 variant) are the main COVID-19 variants circulating in Singapore, together accounting for more than two-thirds of locally sequenced cases. JN.1 is also the variant used in the formulation of the current Covid-19 vaccine,' Singapore's Ministry of Health stated.The JN.1 variant, first identified in August 2023, was classified by the World Health Organisation as a 'variant of interest' in December the same year. It is part of the Omicron BA.2.86 family and is characterised by over 30 mutations.In Thailand, the XEC variant — another Omicron sub-strain — is also in circulation and may have contributed to the surge, especially during public holidays.Experts across the region believe that immunity built from earlier vaccinations or infections is wearing off. Singaporean health authorities pointed out that many of the infected hadn't received booster shots in over a year. Seasonal factors, increased travel, and larger gatherings may also be accelerating the spread.'Taking into account local and global epidemiological data in recent years, the CHP is of the view that Covid-19 has evolved into an endemic disease with a periodic pattern,' said Dr Tsui of Hong Kong's Centre for Health Protection. He added that the city now expects active Covid cycles every six to nine months, mainly due to declining herd immunity and changing variants.India has not officially confirmed any local spread of the JN.1 variant or its sub-lineages. But the government remains alert. 'The Health Ministry remains vigilant and proactive in monitoring the situation closely,' a source told PTI. 'Appropriate measures are in place to safeguard public health.'For now, there's no sign of a significant domestic surge. But the global rise in cases has served as a reminder — the pandemic's grip may have loosened, but it hasn't vanished.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
ICMR's anti-malaria vaccine still 6-7 years away
The Indian Council of Medical Research (ICMR) has invited an expression of interest for technology transfer to commercialise its anti-malaria vaccine candidate that it is developing in partnership with the department of biotechnology, even though the vaccine is likely to take at least six to seven years to be ready for use, according to people familiar with the matter. Malaria continues to pose serious challenges to public health and economies, particularly in the tropical and subtropical regions around the world. (Unsplash) According to the projected timeline, accessed by HT, the 'Good Manufacturing Practice (GMP) production and toxicology studies' will take approximately two years; 'phase 1 clinical trial, including regulatory approval', will take another two years; 'Phase 2b and Phase 3 clinical trials' will take approximately two and a half years; and post-trial regulatory clearance and licensing for marketing would take approximately six months. (Each stage includes a buffer period of ± six months.) The recombinant chimeric multi-stage malaria vaccine (AdFalciVax) is being indigenously developed against plasmodium falciparum— the parasite that predominantly causes severe and fatal malaria, according to ICMR. 'In early stages, the vaccine candidate looks useful in preventing plasmodium falciparum infection in humans and minimising its community transmission,' it added. Malaria continues to pose serious challenges to public health and economies, particularly in the tropical and subtropical regions around the world. According to data shared by the government, globally in 2023, there were almost 263 million estimated malaria cases in 83 malaria-endemic countries, an increase of 11 million cases compared with 2022. India accounted for half of all estimated malaria cases in the South-East Asia region in 2023. ICMR has invited applications from organisations, companies, and manufacturers from across the country. 'ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB)— one of the constituent institutes of ICMR has led development of a technology entitled 'A recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against Plasmodium falciparum'… and ICMR-RMRCBB has technical know-how of process to produce this technology. The pre-clinical validation of this technology has been conducted in collaboration with ICMR-National Institute of Malaria Research (ICMR-NIMR), another constituent institutes of ICMR, and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology, Government of India,' the ICMR invite said. AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of plasmodium falciparum. Country's biomedical research regulator, however, emphasised that the vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. The vaccine has shown excellent efficacy in the preclinical stage of development, ICMR said in a statement. 'Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines (such as RTS,S/AS01 and R21/Matrix-M), including: Broader protection by targeting two vulnerable parasite stages; lower risk of immune evasion and potential for better long-term immunity; extended thermal stability with functionality maintained for over nine months at room temperature; and cost-effective formulation using pharmaceutically acceptable carriers,' the statement added. ICMR further said that it intends to licence the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximize public health benefits, and all collaborations will adhere to ICMR's intellectual property policy. ICMR would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results or data analysis, outcome assessment, safety and efficacy assessment, product improvement, etc. 'Subsequent to the execution of the agreement such companies/manufacturers shall be responsible to pay the Royalty @ 2% on Net sales, as applicable, according to the ICMR Guidelines for Technology Development Collaboration...,' the statement said. It added that the introduction and rollout of malaria vaccines, such as RTS,S and R21/Matrix-M, have shown promise in reducing disease incidence, particularly among young children in high-burden areas. While significant progress has been made in combating malaria, the global burden remains substantial. In order to address the goal of malaria elimination, an improved vaccine with better efficacy needs to induce protection against infection in human hosts as well as block or reduce transmission to the mosquito vector. 'In this proposed technology, we developed a process for the production of P. falciparum recombinant chimeric malaria antigen (AdFalciVax) … and have tested it for improved immunogenicity with different adjuvant formulations… It has been hypothesized that a combination of Pre-erythrocytic/Anti-Infection Vaccines (AIV) with Transmission-blocking Vaccines (TBV) will reduce the force of infection and be more efficacious than an AIV, like RTS,S or R21/Matrix-M alone,' the statement added.
Time of India
2 hours ago
- Time of India
PGI's Rs 490 cr Advanced Neuroscience Centre nears launch by Sept
Chandigarh: India's healthcare system, currently facing a critical shortage of neurologists—with just one specialist available per million people—is on the brink of a major breakthrough. The Postgraduate Institute of Medical Education and Research (PGI), Chandigarh, is preparing to launch its long-awaited Advanced Neuroscience Centre, a Rs 490 crore project that promises to revolutionise neurological and neurosurgical care across the country. Approved in 2017 and with construction beginning in 2020, the centre is now nearing full operationalisation. PGI officials have confirmed that the outpatient department (OPD) is expected to become functional by September, marking a significant milestone in the journey to improve access to specialised brain and spine treatment. Once fully operational, the centre will join the ranks of premier institutions like NIMHANS Bengaluru and AIIMS Delhi's Cardiothoracic and Neurosciences Centre. However, PGI's facility stands out for its integrated model, combining neurology and neurosurgery services under one roof. "This will be the largest such centre in India where both specialities are housed in a single building," said a PGI official. "Beds will be consolidated, not scattered across departments, ensuring seamless care for patients. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo " The project has faced several hurdles over the years. Construction was halted during the Covid pandemic in March, 2020 and resumed with limited labour by June. More recently, delays were caused by the renewal of pollution control clearance from the state pollution control board and the calculation of property tax arrears owed by PGI. Despite these challenges, the administration remains optimistic about the centre's phased rollout. The facility will feature 300 general ward beds, 10 modular operating theatres, dedicated ICUs, 10 High Dependency Unit (HDU) beds, and 30 private ward beds. It will offer advanced sub-specialities such as cerebrovascular surgery, skull base surgery, and spinal functional neurosurgery. A key highlight is the Brain Suite, a specialised operating room designed for complex neurosurgical procedures. While some equipment requests—like a 3T MRI, Bi-plane DSA, and dual-energy CT scan—were scaled down due to budget constraints, PGI faculty believe the centre will still significantly enhance diagnostic and treatment capabilities. "Patients come from all corners of India because of the expertise and affordability PGI offers," said a senior faculty member. The Advanced Neuroscience Centre is expected to serve as a national hub for neurological care, addressing a long-standing gap in specialised treatment. With its integrated approach and cutting-edge infrastructure, the centre is poised to offer a lifeline to thousands of patients who currently struggle to access timely and affordable brain and spine care. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Time of India
5 hours ago
- Time of India
Vitamin B12-rich foods that boost brain health
T hink of vitamin B12 as your brain's behind-the-scenes power source, quietly fueling memory, focus, and mental sharpness while keeping your nerves and red blood cells in check. It's essential for everything from DNA production to preventing your brain from shrinking (yes, literally). The catch? Your body can't make it, so you've got to outsource it, preferably through what's on your plate. If you've been feeling foggy, tired, or moody, low B12 might be part of the problem. Luckily, nature's got your back. Here are some B12-rich foods that can help keep your brain switched on and firing smoothly. Eggs Eggs, especially the yolk, are a great source of B12 and also contain choline, another nutrient your brain loves. A couple of boiled eggs a day can go a long way in supporting memory and cognitive function, especially for vegetarians who might have fewer B12 options. Fish Fatty fish like salmon, sardines, and tuna aren't just heart-friendly, they're brain boosters, too. Loaded with B12 and omega-3s, these fish help protect brain cells, reduce inflammation, and may slow age-related mental decline. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Knee Pain Keeping You Up at Night? This Trick Could Help Instantly Learn More Undo Dairy products From milk to curd, dairy is an easy and familiar source of B12, especially in Indian households. Regular consumption can help improve mental clarity, mood, and alertness, no fancy diet required. Chicken and lean meats Chicken and other lean meats are not only good sources of protein but also rich in B12. They're easy on digestion, help maintain energy throughout the day, and support both brain and body health. Fortified cereals Many breakfast cereals come fortified with B12, perfect for vegetarians or those on the go. Pick whole-grain varieties for an added bonus of fiber and other brain-nourishing nutrients. Paneer Paneer isn't just a vegetarian staple, it also delivers a healthy dose of B12. Including it in your meals a few times a week can support nerve function and help clear out mental cobwebs. Fortified plant-based milks If you're vegan or can't handle dairy, plant-based milks like soy, almond, or oat often come fortified with B12. They blend easily into smoothies, coffee, or even your morning chai. Liver It's not everyone's favorite, but liver is one of the richest natural sources of B12. Even small portions now and then can supercharge your B12 levels and keep your brain in top shape. Shellfish Clams and oysters are B12 powerhouses. They also bring zinc and iron to the table, nutrients that work together to support brain and nerve health. Even a once-a-week seafood dish can make a difference. Nutritional Yeast Often fortified with B12, this cheesy-flavored vegan staple is great sprinkled on popcorn, salads, or pasta. It's a sneaky but tasty way to keep your B12 levels up. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
